Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
What do adult outpatients included in clinical trials know about the investigational drugs being assessed: A cross-sectional study in France.
Fronteau C, Paré M, Benoit P, Tollec S, Hamon C, Schwiertz V, Maillard C, Cransac A, Volteau C, Huon JF, Burgeot V, Tching-Sin M, Guérin C, Flet L. Fronteau C, et al. Among authors: schwiertz v. PLoS One. 2019 Aug 13;14(8):e0220383. doi: 10.1371/journal.pone.0220383. eCollection 2019. PLoS One. 2019. PMID: 31408456 Free PMC article.
SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma.
Fargier E, Ranchon F, Huot L, Guerre P, Safar V, Dony A, Hequet N, Bachy E, Savouroux S, Fronteau C, Tomaré P, Tournamille JF, Schwiertz V, Vantard N, Le Gouill S, Gyan E, Salles G, Rioufol C. Fargier E, et al. Among authors: schwiertz v. Ann Hematol. 2018 Jan;97(1):123-131. doi: 10.1007/s00277-017-3147-y. Epub 2017 Oct 10. Ann Hematol. 2018. PMID: 28993857
SIMulation of Medication Error induced by Clinical Trial drug labeling: the SIMME-CT study.
Dollinger C, Schwiertz V, Sarfati L, Gourc-Berthod C, Guédat MG, Alloux C, Vantard N, Gauthier N, He S, Kiouris E, Caffin AG, Bernard D, Ranchon F, Rioufol C. Dollinger C, et al. Among authors: schwiertz v. Int J Qual Health Care. 2016 Jun;28(3):311-5. doi: 10.1093/intqhc/mzw025. Epub 2016 Mar 13. Int J Qual Health Care. 2016. PMID: 26976831
Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effects.
Périchou J, Ranchon F, Herledan C, Huot L, Larbre V, Carpentier I, Lazareth A, Karlin L, Beny K, Vantard N, Schwiertz V, Caffin AG, Baudouin A, Sesques P, Brisou G, Ghesquières H, Salles G, Rioufol C. Périchou J, et al. Among authors: schwiertz v. PLoS One. 2020 Dec 4;15(12):e0243309. doi: 10.1371/journal.pone.0243309. eCollection 2020. PLoS One. 2020. PMID: 33275634 Free PMC article. Clinical Trial.
Hypersensitivity to oxaliplatin: clinical features and risk factors.
Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, Gourc C, Gauthier N, Guedat MG, He S, Kiouris E, Alloux C, Vial T, Trillet-Lenoir V, Freyer G, Berard F, Rioufol C. Parel M, et al. Among authors: schwiertz v. BMC Pharmacol Toxicol. 2014 Jan 13;15:1. doi: 10.1186/2050-6511-15-1. BMC Pharmacol Toxicol. 2014. PMID: 24417770 Free PMC article.
EPICC study: evaluation of pharmaceutical intervention in cancer care.
Vantard N, Ranchon F, Schwiertz V, Gourc C, Gauthier N, Guedat MG, He S, Kiouris E, Alloux C, You B, Souquet PJ, Freyer G, Salles G, Trillet-Lenoir V, Rioufol C. Vantard N, et al. Among authors: schwiertz v. J Clin Pharm Ther. 2015 Apr;40(2):196-203. doi: 10.1111/jcpt.12242. Epub 2015 Jan 16. J Clin Pharm Ther. 2015. PMID: 25594148
31 results